利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

62 条记录 (耗时 0.026 秒)

    Antimycotic pharmaceutical composition
    2.
    发明授权
    Antimycotic pharmaceutical composition 有权

    公开(公告)号：US10130610B2

    公开(公告)日：2018-11-20

    申请号：US13258114

    申请日：2010-04-09

    申请人： Hirokazu Kobayashi ,  Eiko Kosugi ,  Nobuo Kubota

    发明人： Hirokazu Kobayashi ,  Eiko Kosugi ,  Nobuo Kubota

    IPC分类号： A61K31/4178 ,  A61K9/00 ,  A61K9/08 ,  A61K9/70 ,  A61K47/08 ,  A61K47/10 ,  A61K47/14

    摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.

    Method of identifying abnormal cells by expression levels of ETFB
    4.
    发明授权
    Method of identifying abnormal cells by expression levels of ETFB 有权
    通过ETFB表达水平鉴定异常细胞的方法

    公开(公告)号：US09562912B2

    公开(公告)日：2017-02-07

    申请号：US14342774

    申请日：2011-12-27

    申请人： Shigenari Hirokawa ,  Hiroyuki Kitajima ,  Tomomasa Shimanuki

    发明人： Shigenari Hirokawa ,  Hiroyuki Kitajima ,  Tomomasa Shimanuki

    IPC分类号： C12Q1/68 ,  G01N33/68 ,  G01N33/50 ,  C12N15/113

    CPC分类号： G01N33/6872 ,  C12N15/113 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/5044 ,  G01N33/6893 ,  G01N2800/20

    摘要： Provided is a method for identifying and suppressing abnormal growth of fibroblasts at an early stage. Provided is a method for identifying the growth state of fibroblasts using as an index the level of expression of ETFB (electron transfer flavoprotein beta subunit), comprising: judging, in cases where the level of expression of ETFB is high, that there is a high probability that fibroblasts are abnormally growing; and judging, in cases where the level of expression of ETFB is low, that there is a high probability that fibroblasts are normally growing. Further, by inhibition of ETFB, abnormal growth of fibroblasts can be suppressed.

    摘要翻译： 提供了一种早期鉴别和抑制成纤维细胞异常生长的方法。 提供了使用作为ETFB（电子转移黄素蛋白β亚基）的表达水平的指标来鉴定成纤维细胞的生长状态的方法，其包括：在ETFB的表达水平高的情况下判断为高 成纤维细胞异常生长的可能性 并且在ETFB的表达水平低的情况下判断成纤维细胞正常生长的可能性很高。 此外，通过抑制ETFB，可以抑制成纤维细胞的异常生长。

    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    8.
    发明申请
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 有权
    抗生物药物组合物

    公开(公告)号：US20130090365A1

    公开(公告)日：2013-04-11

    申请号：US13703300

    申请日：2011-06-10

    申请人： Nobuo Kubota ,  Hirokazu Kobayashi ,  Takaaki Masuda

    发明人： Nobuo Kubota ,  Hirokazu Kobayashi ,  Takaaki Masuda

    IPC分类号： A61K31/4178 ,  A61K47/22 ,  A61K47/10 ,  A61K47/14

    CPC分类号： A61K31/4178 ,  A61K9/0014 ,  A61K9/08 ,  A61K31/385 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22

    摘要： An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R1, R2 independently represent hydrogen atom or halogen atom respectively, and at least one of R1, R2 is halogen atom.)

    摘要翻译： 本发明提供一种药物制剂，其在低温区域和高温区域的储存过程中，相对于由通式（1）表示的化合物的溶解稳定性优异。 本发明涉及一种药物组合物，其包含1）由通式（1）表示的化合物和/或其盐和2）多元醇衍生物。 通式（1）（式中，R 1，R 2分别独立地表示氢原子或卤原子，R 1，R 2中的至少一个为卤素原子）